Cartilage oligomeric matrix protein-induced complement activation in systemic sclerosis

Arthritis Research and Therapy

Volumn 15, Issue 6, 2013, Pages

  Otteby, Kaisa E ^a   Holmquist, Emelie ^a   Saxne, Tore ^a   Heinegård, Dick ^a   Hesselstrand, Roger ^a   Blom, Anna M ^a  

^a LUND UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

CARTILAGE OLIGOMERIC MATRIX PROTEIN; COMPLEMENT COMPONENT C3B; IMMUNOGLOBULIN G; COMP PROTEIN, HUMAN;

ADOLESCENT; ADULT; AGED; ARTICLE; COMPLEMENT ACTIVATION; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PROTEIN EXPRESSION; SKIN BIOPSY; SYSTEMIC SCLEROSIS; VERY ELDERLY; YOUNG ADULT; BLOOD; FLUORESCENCE MICROSCOPY; METABOLISM; PHYSIOLOGY; SKIN;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CARTILAGE OLIGOMERIC MATRIX PROTEIN; COMPLEMENT ACTIVATION; COMPLEMENT C3B; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; MALE; MICROSCOPY, FLUORESCENCE; MIDDLE AGED; SCLERODERMA, SYSTEMIC; SKIN; YOUNG ADULT;

EID: 84889971097     PISSN: 14786354     EISSN: 14786362     Source Type: Journal    
DOI: 10.1186/ar4410     Document Type: Article

References (31)

1. Sticherling M. Systemic sclerosis - dermatological aspects. Part 1: pathogenesis, epidemiology, clinical findings. J Dtsch Dermatol Ges 2012, 10:705-718.
2. Fleischmajer R, Gay S, Meigel WN, Perlish JS. Collagen in the cellular and fibrotic stages of scleroderma. Arthritis Rheum 1978, 21:418-428. 10.1002/art.1780210404, 350229.
3. Martin P, Teodoro WR, Velosa AP, de Morais J, Carrasco S, Christmann RB, Goldenstein-Schainberg C, Parra ER, Katayama ML, Sotto MN, Capelozzi VL, Yoshinari NH. Abnormal collagen V deposition in dermis correlates with skin thickening and disease activity in systemic sclerosis. Autoimmun Rev 2012, 11:827-835. 10.1016/j.autrev.2012.02.017, 22406224.
4. Farina G, Lemaire R, Korn JH, Widom RL. Cartilage oligomeric matrix protein is overexpressed by scleroderma dermal fibroblasts. Matrix Biol 2006, 25:213-222. 10.1016/j.matbio.2006.01.007, 16520029.
5. Yamamoto M, Takahashi H, Suzuki C, Naishiro Y, Yamamoto H, Imai K, Shinomura Y, et al. Cartilage oligomeric matrix protein in systemic sclerosis. Rheumatology 2007, 46:1858-1859. 10.1093/rheumatology/kem254, 17895282.
6. Farina G, Lemaire R, Pancari P, Bayle J, Widom RL, Lafyatis R, et al. Cartilage oligomeric matrix protein expression in systemic sclerosis reveals heterogeneity of dermal fibroblast responses to transforming growth factor beta. Ann Rheum Dis 2009, 68:435-441. 10.1136/ard.2007.086850, 18408251.
7. Tan FK, Hildebrand BA, Lester MS, Stivers DN, Pounds S, Zhou X, Wallis DD, Milewicz DM, Reveille JD, Mayes MD, Jin L, Arnett FC, et al. Classification analysis of the transcriptosome of nonlesional cultured dermal fibroblasts from systemic sclerosis patients with early disease. Arthritis Rheum 2005, 52:865-876. 10.1002/art.20871, 15751056.
8. Agarwal P, Zwolanek D, Keene DR, Schulz JN, Blumbach K, Heinegård D, Zaucke F, Paulsson M, Krieg T, Koch M, Eckes B, et al. Collagen XII and XIV, new partners of cartilage oligomeric matrix protein in the skin extracellular matrix suprastructure. J Biol Chem 2012, 287:22549-22559. 10.1074/jbc.M111.335935, 3391150, 22573329.
9. Rosenberg K, Olsson H, Mörgelin M, Heinegård D. Cartilage oligomeric matrix protein shows high affinity zinc-dependent interaction with triple helical collagen. J Biol Chem 1998, 273:20397-20403. 10.1074/jbc.273.32.20397, 9685393.
10. Halasz K, Kassner A, Mörgelin M, Heinegård D. COMP acts as a catalyst in collagen fibrillogenesis. J Biol Chem 2007, 282:31166-31173. 10.1074/jbc.M705735200, 17716974.
11. Hedbom E, Antonsson P, Hjerpe A, Aeschlimann D, Paulsson M, Rosa-Pimentel E, Sommarin Y, Wendel M, Oldberg A, Heinegård D, et al. Cartilage matrix proteins. An acidic oligomeric protein (COMP) detected only in cartilage. J Biol Chem 1992, 267:6132-6136.
12. DiCesare P, Hauser N, Lehman D, Pasumarti S, Paulsson M. Cartilage oligomeric matrix protein (COMP) is an abundant component of tendon. FEBS Lett 1994, 354:237-240. 10.1016/0014-5793(94)01134-6, 7957930.
13. Hesselstrand R, Kassner A, Heinegård D, Saxne T. COMP: a candidate molecule in the pathogenesis of systemic sclerosis with a potential as a disease marker. Ann Rheum Dis 2008, 67:1242-1248.
14. Gheita TA, Hussein H. Cartilage Oligomeric Matrix Protein (COMP) in systemic sclerosis (SSc): role in disease severity and subclinical rheumatoid arthritis overlap. Joint Bone Spine 2012, 79:51-56. 10.1016/j.jbspin.2011.02.022, 21497537.
15. Hesselstrand R, Andréasson K, Wuttge DM, Bozovic G, Scheja A, Saxne T. Increased serum COMP predicts mortality in SSc: results from a longitudinal study of interstitial lung disease. Rheumatology (Oxford) 2012, 51:915-920. 10.1093/rheumatology/ker442, 22253028.
16. Riessen R, Fenchel M, Chen H, Axel DI, Karsch KR, Lawler J, et al. Cartilage oligomeric matrix protein (thrombospondin-5) is expressed by human vascular smooth muscle cells. Arterioscler Thromb Vasc Biol 2001, 21:47-54. 10.1161/01.ATV.21.1.47, 11145932.
17. Kalogerou A, Gelou E, Mountantonakis S, Settas L, Zafiriou E, Sakkas L, et al. Early T cell activation in the skin from patients with systemic sclerosis. Ann Rheum Dis 2005, 64:1233-1235. 10.1136/ard.2004.027094, 1755597, 16014686.
18. Higashi-Kuwata N, Jinnin M, Makino T, Fukushima S, Inoue Y, Muchemwa FC, Yonemura Y, Komohara Y, Takeya M, Mitsuya H, Ihn H, et al. Characterization of monocyte/macrophage subsets in the skin and peripheral blood derived from patients with systemic sclerosis. Arthritis Res Ther 2010, 12:R128. 10.1186/ar3066, 2945018, 20602758.
19. Scala E, Pallotta S, Frezzolini A, Abeni D, Barbieri C, Sampogna F, De Pità O, Puddu P, Paganelli R, Russo G, et al. Cytokine and chemokine levels in systemic sclerosis: relationship with cutaneous and internal organ involvement. Clin Exp Immunol 2004, 138:540-546. 1809238, 15544634.
20. Gourh P, Arnett FC, Assassi S, Tan FK, Huang M, Diekman L, Mayes MD, Reveille JD, Agarwal SK, et al. Plasma cytokine profiles in systemic sclerosis: associations with autoantibody subsets and clinical manifestations. Arthritis Res Ther 2009, 11:R147. 10.1186/ar2821, 2787259, 19799786.
21. Steen VD. Autoantibodies in systemic sclerosis. Semin Arthritis Rheum 2005, 35:35-42. 10.1016/j.semarthrit.2005.03.005, 16084222.
22. Senaldi G, Lupoli S, Vergani D, Black CM. Activation of the complement system in systemic sclerosis. Relationship to clinical severity. Arthritis Rheum 1989, 32:1262-1267. 10.1002/anr.1780321011, 2803327.
23. Wild G, Watkins J, Ward AM, Hughes P, Hume A, Rowell NR, et al. Complement activation in systemic sclerosis. J Clin Lab Immunol 1990, 31:39-41.
24. Sprott H, Muller-Ladner U, Distler O, Gay RE, Barnum SR, Landthaler M, Schölmerich J, Lang B, Gay S, et al. Detection of activated complement complex C5b-9 and complement receptor C5a in skin biopsies of patients with systemic sclerosis (scleroderma). J Rheumatol 2000, 27:402-404.
25. Venneker GT, van den Hoogen FH, Boerbooms AM, Bos JD, Asghar SS. Aberrant expression of membrane cofactor protein and decay-accelerating factor in the endothelium of patients with systemic sclerosis. A possible mechanism of vascular damage. Lab Invest 1994, 70:830-835.
26. Happonen KE, Saxne T, Aspberg A, Mörgelin M, Heinegård D, Blom AM, et al. Regulation of complement by cartilage oligomeric matrix protein allows for a novel molecular diagnostic principle in rheumatoid arthritis. Arthritis Rheum 2010, 62:3574-3583. 10.1002/art.27720, 20737467.
27. Happonen KE, Saxne T, Geborek P, Andersson M, Bengtsson AA, Hesselstrand R, Heinegård D, Blom AM, et al. Serum COMP-C3b complexes in rheumatic diseases and relation to anti-TNF-alpha treatment. Arthritis Res Ther 2012, 14:R15. 10.1186/ar3694, 3392805, 22264230.
28. Souto-Carneiro MM, Burkhardt H, Muller EC, Hermann R, Otto A, Kraetsch HG, Sack U, König A, Heinegård D, Müller-Hermelink HK, Krenn V, et al. Human monoclonal rheumatoid synovial B lymphocyte hybridoma with a new disease-related specificity for cartilage oligomeric matrix protein. J Immunol 2001, 166:4202-4208.
29. Masi AT, Rodnan GP, Medsger TA, Altman RD. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Arthritis Rheum 1980, 25:581-590.
30. LeRoy EC, Black C, Fleischmajer R, Jablonska S, Krieg T, Medsger TA, Rowell N, Wollheim F, et al. Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol 1988, 15:202-205.
31. Sjölander J, Westermark GT, Renström E, Blom AM. Islet amyloid polypeptide triggers limited complement activation and binds complement inhibitor C4b-binding protein, which enhances fibril formation. J Biol Chem 2012, 287:10824-10833. 10.1074/jbc.M111.244285, 3322885, 22334700.